<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39449329</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4468</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Antibodies (Basel, Switzerland)</Title><ISOAbbreviation>Antibodies (Basel)</ISOAbbreviation></Journal><ArticleTitle>Limited Biomarker Potential for IgG Autoantibodies Reactive to Linear Epitopes in Systemic Lupus Erythematosus or Spondyloarthropathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">87</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antib13040087</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Autoantibodies are commonly used as biomarkers in autoimmune diseases, but there are limitations. For example, autoantibody biomarkers have poor sensitivity or specificity in systemic lupus erythematosus and do not exist in the spondyloarthropathies, impairing diagnosis and treatment. While autoantibodies suitable for strong biomarkers may not exist in these conditions, another possibility is that technology has limited their discovery. The purpose of this study was to use a novel high-density peptide array that enables the evaluation of IgG binding to every possible linear antigen in the entire human peptidome, as well as a novel machine learning approach that incorporates ELISA validation predictability in order to discover autoantibodies that could be developed into sensitive and specific markers of lupus or spondyloarthropathy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a peptide array containing the human peptidome, several viral peptidomes, and key post-translational modifications (6 million peptides) to quantify IgG binding in lupus, spondyloarthropathy, rheumatoid arthritis, Sjögren's disease, and control sera. Using ELISA data for 70 peptides, we performed a random forest analysis that evaluated multiple array features to predict which peptides might be good biomarkers, as confirmed by ELISA. We validated the peptide prediction methodology in rheumatoid arthritis and COVID-19, conditions for which the antibody repertoire is well-understood, and then evaluated IgG binding by ELISA to peptides that we predicted would be highly bound specifically in lupus or spondyloarthropathy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our methodology performed well in validation studies, but peptides predicted to be highly and specifically bound in lupus or spondyloarthropathy could not be confirmed by ELISA.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In a comprehensive evaluation of the entire human peptidome, highly sensitive and specific IgG autoantibodies were not identified in lupus or spondyloarthropathy. Thus, the pathogenesis of lupus and spondyloarthropathy may not depend upon unique autoantigens, and other types of molecules should be sought as optimal biomarkers in these conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bashar</LastName><ForeName>S Janna</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-0779-1530</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zihao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mergaert</LastName><ForeName>Aisha M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adyniec</LastName><ForeName>Ryan R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Srishti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amjadi</LastName><ForeName>Maya F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCoy</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9038-878X</Identifier><AffiliationInfo><Affiliation>Department of Statistics, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53726, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelef</LastName><ForeName>Miriam A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-8842-0303</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>W81XWH-18-1-0717</GrantID><Agency>Congressionally Directed Medical Research Programs</Agency><Country /></Grant><Grant><GrantID>T32 AG000213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM140935</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM140935</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002374</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2TR002374</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibodies (Basel)</MedlineTA><NlmUniqueID>101587489</NlmUniqueID><ISSNLinking>2073-4468</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">peptide array</Keyword><Keyword MajorTopicYN="N">spondyloarthropathy</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Z.Z. became employed by Google, A.M.M. by Labcorp Drug Development and then Discovery Life Science, and R.R.A. by Labcorp Drug Development after completing their contributions to the project. S.S.M. received consulting fees from Aurinia, BMS, Novartis, Otuska/Visterra, Horizon, Target RWE, Amgen, iCell, and Kiniksa. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39449329</ArticleId><ArticleId IdType="pmc">PMC11503330</ArticleId><ArticleId IdType="doi">10.3390/antib13040087</ArticleId><ArticleId IdType="pii">antib13040087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Investig. 1998;101:273–281. doi: 10.1172/JCI1316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI1316</ArticleId><ArticleId IdType="pmc">PMC508564</ArticleId><ArticleId IdType="pubmed">9421490</ArticleId></ArticleIdList></Reference><Reference><Citation>Barra L., Pope J.E., Orav J.E., Boire G., Haraoui B., Hitchon C., Keystone E.C., Thorne J.C., Tin D., Bykerk V.P., et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J. Rheumatol. 2014;41:2361–2369. doi: 10.3899/jrheum.140082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.140082</ArticleId><ArticleId IdType="pubmed">25274884</ArticleId></ArticleIdList></Reference><Reference><Citation>Deodhar A., Mittal M., Reilly P., Bao Y., Manthena S., Anderson J., Joshi A. Ankylosing spondylitis diagnosis in US patients with back pain: Identifying providers involved and factors associated with rheumatology referral delay. Clin. Rheumatol. 2016;35:1769–1776. doi: 10.1007/s10067-016-3231-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3231-z</ArticleId><ArticleId IdType="pmc">PMC4914524</ArticleId><ArticleId IdType="pubmed">26987341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt A.G., Lendrem D., Hargreaves B., Aslam O., Galloway J.B., Isaacs J.D. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: Validation of a single-centre observation using national audit data. Rheumatology. 2016;55:1843–1848. doi: 10.1093/rheumatology/kew261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew261</ArticleId><ArticleId IdType="pmc">PMC5034219</ArticleId><ArticleId IdType="pubmed">27373893</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo M.R., Baek H.L., Yoon H.H., Ryu H.J., Choi H.J., Baek H.J., Ko K.P. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin. Rheumatol. 2015;34:1397–1405. doi: 10.1007/s10067-014-2768-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2768-y</ArticleId><ArticleId IdType="pubmed">25185731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward D.J., Johnson G.D., Holborow E.J. Antinuclear Factor in Rheumatoid Arthritis, Its Incidence and Clinical Significance. Ann. Rheum. Dis. 1964;23:306–310. doi: 10.1136/ard.23.4.306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.23.4.306</ArticleId><ArticleId IdType="pmc">PMC1030931</ArticleId><ArticleId IdType="pubmed">14178017</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J.S., Anderson J.R., Bloch K.J., Buchanan W.W., Bunim J.J. Antinuclear and Precipitating Auto-Antibodies in Sjoegren’s Syndrome. Ann. Rheum. Dis. 1965;24:16–22. doi: 10.1136/ard.24.1.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.24.1.16</ArticleId><ArticleId IdType="pmc">PMC1030909</ArticleId><ArticleId IdType="pubmed">14261074</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmi C., Ceribelli A., Generali E., Scire C.A., Alborghetti F., Colloredo G., Porrati L., Achenza M.I., De Santis M., Cavaciocchi F., et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun. Rev. 2016;15:162–166. doi: 10.1016/j.autrev.2015.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.10.007</ArticleId><ArticleId IdType="pubmed">26524640</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beers J., Schreurs M.W.J. Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus. J. Transl. Autoimmun. 2022;5:100155. doi: 10.1016/j.jtauto.2022.100155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100155</ArticleId><ArticleId IdType="pmc">PMC9026971</ArticleId><ArticleId IdType="pubmed">35464346</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D.A., Manson J.J., Ehrenstein M.R., Rahman A. Fifty years of anti-ds DNA antibodies: Are we approaching journey’s end? Rheumatology. 2007;46:1052–1056. doi: 10.1093/rheumatology/kem112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem112</ArticleId><ArticleId IdType="pubmed">17500073</ArticleId></ArticleIdList></Reference><Reference><Citation>Engmark M., Andersen M.R., Laustsen A.H., Patel J., Sullivan E., de Masi F., Hansen C.S., Kringelum J.V., Lomonte B., Gutierrez J.M., et al. High-throughput immuno-profiling of mamba (Dendroaspis) venom toxin epitopes using high-density peptide microarrays. Sci. Rep. 2016;6:36629. doi: 10.1038/srep36629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36629</ArticleId><ArticleId IdType="pmc">PMC5100549</ArticleId><ArticleId IdType="pubmed">27824133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.S., Dufva M., Bogh K.L., Sullivan E., Patel J., Eiwegger T., Szepfalusi Z., Nielsen M., Christiansen A. Linear epitope mapping of peanut allergens demonstrates individualized and persistent antibody-binding patterns. J. Allergy Clin. Immunol. 2016;138:1728–1730. doi: 10.1016/j.jaci.2016.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.06.019</ArticleId><ArticleId IdType="pubmed">27523433</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte J.G., Blackburn J.M. Advances in the development of human protein microarrays. Expert. Rev. Proteom. 2017;14:627–641. doi: 10.1080/14789450.2017.1347042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2017.1347042</ArticleId><ArticleId IdType="pubmed">28644690</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey J.D. A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B Stat. Methodol. 2002;78:781–804. doi: 10.1111/1467-9868.00346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-9868.00346</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M. False discovery rates: A new deal. Biostatistics. 2017;18:275–294. doi: 10.1093/biostatistics/kxw041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxw041</ArticleId><ArticleId IdType="pmc">PMC5379932</ArticleId><ArticleId IdType="pubmed">27756721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Mergaert A.M., Ong I.M., Shelef M.A., Newton M.A. MixTwice: Large-scale hypothesis testing for peptide arrays by variance mixing. Bioinformatics. 2021;37:2637–2643. doi: 10.1093/bioinformatics/btab162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab162</ArticleId><ArticleId IdType="pmc">PMC8428605</ArticleId><ArticleId IdType="pubmed">33693483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergaert A.M., Zheng Z.H., Denny M.F., Amjadi M.F., Bashar S.J., Newton M.A., Malmström V., Grönwall C., McCoy S.S., Shelef M.A. Rheumatoid Factor and Anti-Modified Protein Antibody Reactivities Converge on IgG Epitopes. Arthritis Rheumatol. 2022;74:984–991. doi: 10.1002/art.42064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42064</ArticleId><ArticleId IdType="pmc">PMC9156533</ArticleId><ArticleId IdType="pubmed">35001558</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., 3rd, Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581. doi: 10.1002/art.27584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27584</ArticleId><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., Schiodt M., Umehara H., Vivino F., Zhao Y., et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: A data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475–487. doi: 10.1002/acr.21591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21591</ArticleId><ArticleId IdType="pmc">PMC3349440</ArticleId><ArticleId IdType="pubmed">22563590</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker M., Zheng Z., Lasarev M.R., Larsen M.C., Vande Loo A., Alexandridis R.A., Newton M.A., Shelef M.A., McCoy S.S. Novel autoantibodies help diagnose anti-SSA antibody negative Sjogren disease and predict abnormal labial salivary gland pathology. Ann. Rheum. Dis. 2024;83:1169–1180. doi: 10.1136/ard-2023-224936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2023-224936</ArticleId><ArticleId IdType="pubmed">38702176</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Mergaert A.M., Fahmy L.M., Bawadekar M., Holmes C.L., Ong I.M., Bridges A.J., Newton M.A., Shelef M.A. Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis. Arthritis Rheumatol. 2020;72:262–272. doi: 10.1002/art.41074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41074</ArticleId><ArticleId IdType="pmc">PMC6994383</ArticleId><ArticleId IdType="pubmed">31397047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandian A., Forsstrom B., Haggmark-Manberg A., Schwenk J.M., Uhlen M., Nilsson P., Ayoglu B. Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy. J. Proteome Res. 2017;16:1300–1314. doi: 10.1021/acs.jproteome.6b00916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.6b00916</ArticleId><ArticleId IdType="pubmed">28121444</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen J., Forsstrom B., Sahlstrom P., Odowd V., Israelsson L., Krishnamurthy A., Badreh S., Mathsson Alm L., Compson J., Ramskold D., et al. Human plasma cell derived monoclonal antibodies to post-translationally modified proteins recognize amino acid motifs rather than specific proteins. Arthritis Rheumatol. 2018;71:196–209. doi: 10.1002/art.40699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40699</ArticleId><ArticleId IdType="pmc">PMC6563427</ArticleId><ArticleId IdType="pubmed">30152202</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen W., Ko F.C., Patel J., Lyamichev V., Albert T., Benz J., Rudolph M.G., Bergmann F., Streidl T., Kratzsch P., et al. Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins. J. Biol. Chem. 2017;292:15622–15635. doi: 10.1074/jbc.M117.797811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.797811</ArticleId><ArticleId IdType="pmc">PMC5612097</ArticleId><ArticleId IdType="pubmed">28751378</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random Forests. Mach. Learn. 2001;45:5–32. doi: 10.1023/A:1010933404324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010933404324</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw A., Wiener M. Classification and regression by randomforest. R News. 2002;2:18–22.</Citation></Reference><Reference><Citation>Henderson N.C., Newton M.A. Making the cut: Improved ranking and selection for large-scale inference. J. R. Stat. Soc. Ser. B Stat. Methodol. 2016;78:781–804. doi: 10.1111/rssb.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/rssb.12131</ArticleId><ArticleId IdType="pmc">PMC4996506</ArticleId><ArticleId IdType="pubmed">27570475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey T.L., Johnson J., Grant C.E., Noble W.S. The MEME Suite. Nucleic Acids Res. 2015;43:W39–W49. doi: 10.1093/nar/gkv416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv416</ArticleId><ArticleId IdType="pmc">PMC4489269</ArticleId><ArticleId IdType="pubmed">25953851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlstrom P., Hansson M., Steen J., Amara K., Titcombe P.J., Forsstrom B., Stalesen R., Israelsson L., Piccoli L., Lundberg K., et al. Different hierarchies of anti-modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol. 2020;72:1643–1657. doi: 10.1002/art.41385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41385</ArticleId><ArticleId IdType="pubmed">32501655</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffron A.S., McIlwain S.J., Amjadi M.F., Baker D.A., Khullar S., Armbrust T., Halfmann P.J., Kawaoka Y., Sethi A.K., Palmenberg A.C., et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 2021;19:e3001265. doi: 10.1371/journal.pbio.3001265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001265</ArticleId><ArticleId IdType="pmc">PMC8245122</ArticleId><ArticleId IdType="pubmed">34143766</ArticleId></ArticleIdList></Reference><Reference><Citation>Amjadi M.F., Adyniec R.R., Gupta S., Bashar S.J., Mergaert A.M., Braun K.M., Moreno G.K., O’Connor D.H., Friedrich T.C., Safdar N., et al. Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination. J. Infect. Dis. 2022;226:1897–1902. doi: 10.1093/infdis/jiac263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac263</ArticleId><ArticleId IdType="pmc">PMC9278254</ArticleId><ArticleId IdType="pubmed">35758987</ArticleId></ArticleIdList></Reference><Reference><Citation>Koussiouris J., Chandran V. Autoantibodies in psoriatic disease. Adv. Clin. Chem. 2023;115:135–174. doi: 10.1016/bs.acc.2023.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acc.2023.03.006</ArticleId><ArticleId IdType="pubmed">37673519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.G., Sohn D.H., Zhao X., Sokolove J., Lindstrom T.M., Yoo B., Lee C.K., Reveille J.D., Taurog J.D., Robinson W.H. Role of PPM1A and anti-PPM1A Autoantibodies in Ankylosing Spondylitis. Arthritis Rheumatol. 2014;66:2793. doi: 10.1002/art.38763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38763</ArticleId><ArticleId IdType="pmc">PMC4198528</ArticleId><ArticleId IdType="pubmed">24980965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C., Sibani S., Trudgian D., Fischer R., Kessler B., LaBaer J., Bowness P. Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol. Cell Proteom. 2012;11:M9 00384. doi: 10.1074/mcp.M9.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M9.00384</ArticleId><ArticleId IdType="pmc">PMC3277774</ArticleId><ArticleId IdType="pubmed">22311593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.S., Lee E.J., Lee J.H., Hong S.C., Lee C.K., Yoo B., Oh J.S., Lee S.H., Kim T.J., Lee S.H., et al. Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents. J. Clin. Med. 2020;9:3968. doi: 10.3390/jcm9123968.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9123968</ArticleId><ArticleId IdType="pmc">PMC7762424</ArticleId><ArticleId IdType="pubmed">33297507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M.H., Nigrovic P.A. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight. 2019;4:125278. doi: 10.1172/jci.insight.125278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.125278</ArticleId><ArticleId IdType="pmc">PMC6483516</ArticleId><ArticleId IdType="pubmed">30843881</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefano L., Bugatti S., Mazzucchelli I., Rossi S., Xoxi B., Bozzalla Cassione E., Luvaro T., Montecucco C., Manzo A. Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis. Rheumatology. 2023;63:1322–1331. doi: 10.1093/rheumatology/kead378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead378</ArticleId><ArticleId IdType="pubmed">37481716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F.L., Lai D.Y., Ding H.H., Tang Y.J., Xu Z.W., Ma M.L., Guo S.J., Wang J.F., Shen N., Zhao X.D., et al. Identification of Serum Biomarkers for Systemic Lupus Erythematosus Using a Library of Phage Displayed Random Peptides and Deep Sequencing. Mol. Cell Proteom. 2019;18:1851–1863. doi: 10.1074/mcp.RA119.001582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.RA119.001582</ArticleId><ArticleId IdType="pmc">PMC6731078</ArticleId><ArticleId IdType="pubmed">31308251</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang H.X., Yin X., Li X., Li H., Zhang X., Wang Z., Qiu Y.R. Screening epitope peptides based on a phage-displayed random peptide and peptide microarrays to contribute to improving the diagnostic efficiency of systemic lupus erythematosus. Immunol. Lett. 2023;259:30–36. doi: 10.1016/j.imlet.2023.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2023.05.008</ArticleId><ArticleId IdType="pubmed">37247788</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford P., Sherma N.D., Peterson M., Diehnelt C.W. A Peptide Microarray Platform Approach for Discovery of Immunodominant Antibody Epitopes. Anal. Chem. 2024;96:14524–14530. doi: 10.1021/acs.analchem.4c02806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.4c02806</ArticleId><ArticleId IdType="pubmed">39207871</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Spezia P.G., Maggi F. Subsequent Waves of Convergent Evolution in SARS-CoV-2 Genes and Proteins. Vaccines. 2024;12:887. doi: 10.3390/vaccines12080887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12080887</ArticleId><ArticleId IdType="pmc">PMC11358953</ArticleId><ArticleId IdType="pubmed">39204013</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng M., Dou X., Zhang X., Yan M., Xiong D., Jiang R., Ou T., Tang A., Yu X., Zhu F., et al. Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. Front. Immunol. 2022;13:938378. doi: 10.3389/fimmu.2022.938378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.938378</ArticleId><ArticleId IdType="pmc">PMC9397116</ArticleId><ArticleId IdType="pubmed">36016943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>